Granulocyte Colony Stimulating Factor (G-CSF) for Bone Marrow Transplant (BMT)
Status:
Completed
Trial end date:
2011-11-01
Target enrollment:
Participant gender:
Summary
The major purpose of this study is to evaluate the curative potential of white cell growth
hormone (G-CSF)-stimulated bone marrow cells in allogeneic bone marrow transplants. Patients
with cancers or blood diseases, who have poor potential for a cure with standard treatment,
will be able to participate in the study. Donors will receive the white cell growth hormone
(G-CSF) as a shot (injection) in their arm once a day for three days before they donate their
bone marrow cells. Total body irradiation and/or chemotherapy will be given first to prepare
the patient's body for the infusion of new bone marrow cells from the donor. Two medicines
(cyclosporine and methotrexate) will be used to prevent the new bone marrow cells (graft)
from attacking the patient's body (host) (graft-versus-host disease; GVHD). Certain safety
checkpoints were built into the study if unwanted/unexpected events were to occur. If the
outcomes appear better than could be expected, this will provide a bridge to extend this
current approach for other innovative therapies.